{"name":"Actinium Pharmaceuticals","slug":"actinium-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":81000,"revenueGrowth":0,"grossMargin":0,"rdSpend":30045000,"netIncome":-38243000,"cash":76899000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2023"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4gJBVV95cUxQZWdaS0hWc0pXSjBLWmFtT1hUV2RPQ1lnel9LY1NobU5Gb1o1dHBrOFlnR2M4UG5fSExfZWRkd003TkZZR1YxMzI0V3NXRnIyVzlVRHhVZEZLVXBqYmFTTTVSQTZSQUNmRDBsNXVwem0yMjkxYUhwMEwydWlSTmxRVlV6Wms4WVRDZ253RF9tVHR3QVdPVFdzN2lSNzNhblJ3ZUw3NTlQbk9wdk53OWlEQmplZ1lOb3BOTkJFY1VpOUNUYnNsYnNBdEN0LUl6Zks3WHAwZFhESUowemVNMUJ1TzZTLVFNOERQNjIwLWNVOEZvMzc0UFczWDE4Qk9vUExKMDRrdVNkbV9HaTdxbzJHNXlsbVJaaUU0ZFF1b2hxRWRoeG5QSDVnU0JVeDlCVmhvVnV0aEtNbFM0TnBHWGJTbDhfRzdpc1kzREJuS0RsclI1bnZoT2FHNzI1ZGRxTl82alE?oc=5","date":"2026-04-06","type":"trial","source":"PR Newswire","summary":"Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting - PR Newswi","headline":"Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechan","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: ANNUAL REPORT","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPR29XamwzUWlWRGN5UGJUNWxIbWxTcVdwRE1feGl5MVE5WFBKajktVHBPcjY5Z2ZYenh3bGZGcElyV1ZyYjdjbGo5ZklkZnZteHdDcjBTWTc2UE9oOTRZc05NT3F6bG9fODFBdVhqOHFoMDc5THR0MjFVUFdpMTZPUHNJZGhOMXRJVUZpV2Nvd0xPaC1TeEt0cG95QldMaXdtcmdwOHhzS2g5QWNY?oc=5","date":"2026-02-17","type":"pipeline","source":"BioSpace","summary":"Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand - BioSpace","headline":"Radiopharma Sector Races To Secure Actinium-225 Supply as Pipelines Expand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNLVkzWDF1MWMwZnhxQnE5UXJCS3I5alFoR2J6TUZMWnRFMmFWZHp2SG00ajAxbm1tYzFSblZlOUVMTnJpV291eWt0alFRVUlrZnY1bnJyNDdVYzlzdDV5dkZobVd5dkllai1zV01TdmQtR1BweHZkRFg4ZHlVTU5kYjYweTd5VE55bks0azdvZVJwYUtCTDVqcS1EYjN1VEpNVUIyVnowak9hb1BtSFFhUmk0Y1lVMFF3?oc=5","date":"2026-02-13","type":"pipeline","source":"Stock Titan","summary":"Actinium Pharmaceuticals (NYSE: ATNM) CFO resigns; CEO adds finance role - Stock Titan","headline":"Actinium Pharmaceuticals (NYSE: ATNM) CFO resigns; CEO adds finance role","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQN1lHSTF1Q0t1bDBDR3ZrMlVoMG56bWxVTHdCWU11RGE3enBYNEExa1I0M0FVaTlCYWpBM1R5ZTVNVmNLdFJsQW01YjhuZVQ1Wmc2OGtOLW8ybmxUMVpBcWVkaTF5YmhjRkdTUktpcVlfTjNkazBRTVRXeDJENDBOTGZrNDJ2V2tJYmI1YUJ2a3V3Z3hWSkxoLTVGWC1hSUV6Uk42TGxNRWYzdw?oc=5","date":"2025-12-19","type":"pipeline","source":"The Pharma Letter","summary":"AstraZeneca locks in long-term actinium-225 supply with Niowave - The Pharma Letter","headline":"AstraZeneca locks in long-term actinium-225 supply with Niowave","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBMeFJxNUVaeF9vUXdDWjQ3dUozeWFlMHhZSFJBUlg0TlB1eGoyZGtQSGVPMTh6NmNrc2hZSUJkaTIybzU4VkpHejBGWGw4TjNfeWFQLW9sVQ?oc=5","date":"2025-12-02","type":"pipeline","source":"Oncodaily","summary":"Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development - Oncodaily","headline":"Jeri Kim: Thrilled to Join Actinium Pharmaceuticals as VP, Head of Solid Tumor Clinical Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZjV0NHdHcW9NamZqMms0YVc5cWhPaXoyRExLMS1YckVXczJRd2FIbWNrdmUtdzN6cFJ4VVRzak9samttZlZWd3FfQ3lyYS1qYzV3QWpqUHNqdTVqbkdxNzJYOWUyU3dldXBHY3Q4MDBUMGtFVXJRZktHVW1fWFV3QmFGbDlfV3ZYSnl4bElycDBFSHpZMjhDeTBLUlF4azZLaVpyS0JIUEN5aFdYT1VPNnYtV1ctekwy?oc=5","date":"2025-12-01","type":"pipeline","source":"Stock Titan","summary":"Actinium Pharma details ATNM-400 in resistant breast cancer | ATNM Stock News - Stock Titan","headline":"Actinium Pharma details ATNM-400 in resistant breast cancer | ATNM Stock News","sentiment":"neutral"},{"date":"2025-11-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxON1dudkhCY0VWajFxVzZGSlRPeWxEVXdJdTR3X1NETHo0aG5LcVVlX0FUNUxhaUp1bzU1NlNsUGc1YlRDOHNYanpRM0N5dTB1S2JqeWFqVTRUT195S3ZEWFc4VHVRNFgyc095WjFuWGFrTGxWWHRfZDVLRkp2cS1mRWFMTFh5VEQ1ZVp3RzFoclBrLU9PcElOc2FtcFltM0JOdkx1N3I0VEN6bzgwNlBlbXhhemh0elRyUk9mc29nbDdfY055MFRDUkVMNHk?oc=5","date":"2025-11-17","type":"pipeline","source":"TMX Newsfile","summary":"The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet - TMX Newsfile","headline":"The Race for the Global Radiotherapy Cancer Market; Actinium Pharmaceuticals' (ATNM) Big Bet","sentiment":"neutral"},{"date":"2025-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-13","type":"trial","source":"PR Newswire","summary":"Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Confer","headline":"Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, wi","sentiment":"neutral"},{"date":"2025-08-08","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-05-09","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-05-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":81000,"revenuePeriod":"2023-12-31","revenueHistory":[{"value":81000,"period":"2023-12-31"},{"value":81000,"period":"2023-12-31"},{"value":1030000,"period":"2022-12-31"},{"value":1030000,"period":"2022-12-31"},{"value":1144000,"period":"2021-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":30045000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-38243000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":76899000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}